MGC Pharmaceuticals' proprietary product, ArtemiC, has received approval from the Food and Drug Authority in Saudi Arabia and is now available as an over-the-counter dietary supplement.
The approval follows successful Phase II clinical trials and European studies showcasing ArtemiC's effectiveness in aiding the recovery of COVID-19 and long-term COVID-19 patients.
MGC Pharma's agent, Capital Blossom, played a key role in securing Saudi FDA approval, and the company anticipates potential commercial orders as it collaborates closely with Capital Blossom in the specified regions.
ArtemiC utilises GraftBio SNEDD technology, demonstrating a comprehensive safety and efficacy profile in clinical trials and offering benefits such as preventing deterioration, achieving faster clinical improvement, and reducing symptoms and pain associated with COVID-19.